Objective Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability remain unclear. This study aimed to identify predictors of variability in ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot ...

Novo Nordisk is advancing its research into obesity treatments by launching new trials for its experimental drug, CagriSema. This decision follows market disappointment after previous trial results.

While the initial market reaction to Novo’s more enhanced CagriSema weight loss treatment was negative, we believe this is a more potent formulation that can better compete with Lilly’s suite.

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...

LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...

LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema ...

However, not all news has been positive. Novo Nordisk faced setbacks with its CagriSema obesity treatment, as the results from the REDEFINE-1 trial were disappointing, showing lower-than-expected ...

The Novo Nordisk class action lawsuit further alleges that on December 20, 2024, defendants published headline results from their REDEFINE-1 CagriSema obesity trial, disclosing that “[t]he ...

The Allegations: Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo’s Phase 3 CagriSema Study on Obesity According to the complaint ...

In December, the share price fell by around 20% following the announcement of trial results for their next-generation weight loss drug, CagriSema. On Friday, the stock, however, saw a much-needed ...